Table 3.
Base case results: costs and QALYs over 30 years
| Canagliflozin 300 mg | Dapagliflozin 10 mg | Difference | |
|---|---|---|---|
| Costs (discounted), $ | |||
| Macrovascular | |||
| MI | 11,500 | 11,667 | – 166 |
| IHD | 4984 | 5029 | – 44 |
| CHF | 3068 | 3108 | – 40 |
| Stroke | 6965 | 7079 | – 114 |
| Microvascular | |||
| Retinopathy | 795 | 808 | – 13 |
| CKD | 6595 | 6645 | – 51 |
| Neuropathy | 3571 | 3593 | – 22 |
| AHA | |||
| Oral agents | 61,130 | 61,574 | – 444 |
| Insulin | 69,135 | 82,159 | – 13,023 |
| Prescription treatment | |||
| Hypoglycemia | 177 | 209 | – 31 |
| AEs | 243 | 264 | – 21 |
| Hypertension | 323 | 385 | – 62 |
| Dyslipidemia | 757 | 715 | 42 |
| Total costs, $ | 169,244 | 183,235 | – 13,991 |
| Health indicators (discounted) | |||
| LYs | 14.33 | 14.31 | 0.02 |
| QALYs | 10.04 | 9.96 | 0.08 |
| Survival, %a | 23.7 | 23.6 | 0.1 |
| Cost per QALY, $ | Dominating | ||
AE adverse event, AHA anti-hyperglycemic agent, CHF congestive heart failure, CKD chronic kidney disease, IHD ischemic heart disease, LY life-year, MI myocardial infarction, QALY quality-adjusted life-year
aPercentage alive at end of simulation